List of Industry Partners
Contact: 60064 North Chicago, United States of America, Kristina Bokenewicz, email@example.com, www.abbvie.com
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube, and LinkedIn.
Contact: 8045 Zurich, Switzerland
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion developed and commercializes SOLIRIS® (eculizumab), the first and only approved complement inhibitor to treat patients with atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), refractory generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). As the global leader in complement inhibition, Alexion is leveraging its experience in complement biology to pursue novel molecules and targets in the complement cascade. Alexion’s development efforts focus the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care.
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives. Founded in 2002 on the bold vision to turn scientific possibility into reality, Alnylam has a robust discovery platform and deep pipeline of investigational medicines, including several programs in late-stage clinical development. Patients are at the core of everything we do; their needs drive our discoveries and their stories further our commitment to delivering innovative therapies.
For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
Contact: 6300 Zug, Switzerland, firstname.lastname@example.org
Contact: 6300 Zug, Switzerland, www.arvelletx.com
Angelini Pharma, part of the privately owned Angelini Group, is a leader in healthcare, focused on the fields of Central Nervous System (CNS), Rare Diseases and Consumer Health. The company operates directly in 25 countries employing more than 3.000 people. Its products are marketed in over 70 countries. In 2021, as part of its global strategy, Angelini Pharma strengthened its positioning in the CNS area with the acquisition of Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on innovative treatments for patients suffering from CNS disorders.
For more information, please visit www.angelinipharma.com
Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating its lead candidate, efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan.
For more information, visit www.argenx.com and follow us on LinkedIn and Twitter.
Contact: À Av. Siderurgia Nacional, 4745-457 Coronado, Portugal, www.bial.com
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company. We specialise in innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson's disease. We are highly committed to improving the quality of life for People with Parkinson's disease.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
Cannabinoid Education 360 is a new educational initiative, developed by GW Pharmaceuticals, that delivers easily accessible, evidence-based, balanced information on cannabinoids and cannabis-based medicines and products.
Our ambition is to provide a full 360-degree perspective on what is really known about the science of cannabinoids, the research behind cannabis-based medicines, and the laws and policy frameworks that regulate them. We want to help dispel any myths and provide clarity around this important, yet complex field of medicine.
Please visit www.cannabinoideducation360.com
Contact: 1214 Vernier-Geneve, Switzerland, www.lilly.com
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries.
Grifols' commitment to Alzheimer's disease research began more than 15 years ago, when the company began exploring the potential of plasma therapies to treat this devastating neurodegenerative disease.
The AMBAR trial (Alzheimer Management by Albumin Replacement) represents one of our most ambitious clinical trials to date.
(url: AMBAR | Grifols)
Contact: Cambridge, United Kingdom
GW Pharmaceuticals is a UK-based biopharmaceutical company that has established a world-leading position in cannabinoid science and medicine and was listed as one of TIME magazine’s ‘50 Genius Companies Inventing the Future, 2018’. Our mission is to unlock the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials, to improve the lives of seriously ill patients. Our pioneering work has led to the regulatory approval of world-first, potentially life-improving, cannabis-based medicines.
Patients are our key focus, and improving their quality of life is our motivation.
Job code: VV-MED-20116
Date of preparation: May 2021
Contact: 4070 Basel, Switzerland, +41616881111, email@example.com, www.roche.com
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
At Horizon, we believe science and compassion must work together to transform lives. A company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases, we apply scientific expertise and courage to bring clinically meaningful therapies to patients.
That’s why we think differently about research and development, so we can deliver in new ways for the patients and families we serve.
We believe our responsibility also extends to the communities where we live and work, which is why we are committed to helping transform and better the lives of those who need it most.
To make a bigger difference, we nurture a work environment that reflects the diversity of our patients. We build teams who work together with speed and urgency, because each extra day it takes to get something done is an extra day that someone may not have the medicine or support they need. Because at Horizon, success is measured by the number of lives we touch, the number of lives we change and those we work tirelessly to help save.
If you want to know more please visit: https://www.horizontherapeutics.com
Contact: 2340 Beerse, Belgium, www.janssen.com
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep medicine and movement disorders, and in oncology, including hematologic and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
Millions of people worldwide live with brain diseases, and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement, and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,800 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs, and our products are available in more than 100 countries. We have research centers in Denmark and the US, and our production facilities are located in Denmark, France, and Italy. Lundbeck generated revenue of DKK 17 billion in 2019 (EUR 2.3 billion; USD 2.6 billion).
At the biopharma business of Merck, we have a long history of focusing on the needs of our customers and patients and we are constantly seeking innovative solutions to advance the state of care in the area of multiple sclerosis (MS). We are committed to developing new treatment options and devices, as well as enhanced patient support services for people living with a neurological disease. Our MS product portfolio includes two complementary products, Rebif ® (interferon beta-1a) for relapsing forms of multiple sclerosis (MS), and MAVENCLAD ® (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis (MS). For further details, please visit: www.merckneurology.com
With our commitment to providing comprehensive solutions across the full spectrum of neurodiagnostic care, Natus Neuro delivers advanced technology and systems across all diagnostic modalities. With a history that spans over 80 years, we have been advancing the quality of patient care in the fields of EEG, EMG, EP, ICU, IOM, LTM, PSG, Sleep research and application products.
We continue to manufacture products, software and solutions that provide detection, trending and monitoring for a range of conditions, including seizures, epilepsy and other disorders that affect the brain. Natus Neuro is comprised of the most widely used and trusted names in the industry, including Nicolet®, TECA®, Dantec®, Schwarzer and Grass®.
Natus Medical Incorporated is the global brand clinicians depend on when diagnosing and treating disorders of the central nervous and sensory systems to improve patient outcomes. For more information, please visit natus.com
Novartis is a leading global medicines company that is reimagining medicine to improve and extend people’s lives, using innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. Find out more at www.novartis.com.
NeuroDerm is a pharmaceutical - medtech company, and wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation, developing next-generation treatments for the central nervous system (CNS) that will make a meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and enhance clinical efficacy.
Contact: EC4N 6EU London, United Kingdom, medinfo(at)orchard-tx.com
Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.
Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Contact: NY 10017 New York, USA, +1 212-733-2323, info@Pfizer.com, www.pfizer.com
Pfizer Inc.: Breakthroughs that change patients’ lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
As the specialty care global business arm of Sanofi, Sanofi Genzyme is committed to meeting significant unmet medical needs. With a well-established heritage in multiple sclerosis, we continue to forge the way in neurology, seeking to provide hope where none existed before, developing innovative approaches to treatments based on patient insights, scientific expertise, and cutting-edge technology. By partnering with scientific, healthcare and patient communities, we continue to build on over 40 years of collaboration and inspiration, understanding and experience, empathy and knowledge to drive the development of potential new therapies and to help change what it means to live with a neurological disease. Learn more about these partnerships and possibilities at www.sanofi.com.
Contact: 1019GM Amsterdam, Netherlands, Job den Hollander, Job.Den.Hollander@Tevaeu.com, www.tevapharm.com
Teva Pharmaceutical Industries Ltd.
Teva makes life-saving and life improving medicines more accessible for millions of people around the world. We focus on treatments for migraine, conditions of the central nervous system including pain, as well as respiratory conditions like asthma and COPD and have a portfolio in oncology. Our mission is to be a global leader in generics and biopharmaceuticals improving the lives of patients around the globe.
Building on more than a century-old legacy we have an established presence in generics, specialty, over-the-counter (OTC) and active pharmaceutical ingredients (API). With a fully integrated R&D function, strong operational base and global infrastructure and scale we invest millions of dollars to help our scientists find the next breakthrough.
We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 40,000 professionals, committed to improving the lives of millions of patients.
Learn more at www.tevapharm.com.
TG Therapeutics was founded with one broad mission: to develop novel treatment options for patients with auto-immune disorders and B-cell malignancies. Our dedication to this mission and hard work since our inception has brought us to where we are today with five drug candidates in clinical development, including ublituximab, a glycoengineered anti-CD20 monoclonal antibody, which is currently being evaluated in the ULTIMATE I & II Phase 3 trials in relapsing MS.
Our commitment to patients, however, goes beyond the science. We believe in challenging the status quo to create innovative solutions to support our patients, enhance patient care, and overcome access hurdles. Visit TGTherapeutics.com to learn more about our fearless commitment to our patients.
UCB (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. We are Inspired by Patients. Driven by Science. Follow us on Twitter: @UCB_news.
Zambon Spa is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives. Based on a valuable heritage but strongly focused on the future, its goal is to improve people’s health through the development of innovative and quality medicines.
Zambon is present in 23 countries with subsidiaries in three different Continents – Europe, America and Asia – and 2,533 employees, with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 87 countries. The company is currently pursuing a new challenge, working on the treatment of specialties and rare diseases, such as Parkinson’s disease and Cystic Fibrosis and is well-established in 3 therapeutic areas: respiratory, pain and women’s care.
Zambon is headquartered in Milan and was established in 1906 in Vicenza. Throughout its history, Zambon has always been standing out for its ability to innovate and bring its products to solid and organic growth, covering more markets globally.
For details on Zambon please visit www.zambon.com